BofA Securities reiterated its Buy rating on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), with a steady price target of GBP145.00. The firm's positive stance is based on the pharmaceutical giant's ...

Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

In a new book, pediatric infectious disease specialist Dr. Adam Ratner details the history of measles, a virus that’s often a ...

As more parents in the U.S. push back against routine vaccinations for children, the new book "Booster Shots" makes the case that measles remains a threat that shouldn't be underestimated.

DUBAI, UAE – Media OutReach Newswire – 28 January 2025 – AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place to work across the ...

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

As COVID-19 raged around the world five years ago, London community nurse Beverly Summers found herself on the frontline of ...

A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

(MENAFN- The Arabian Post) DUBAI, UAE – media OutReach Newswire – 28 January 2025 – AstraZeneca, a leading multinational Pharmaceutical and biotechnology company, has been recognized as the ...